Turn Therapeutics (TTRX) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Turn Therapeutics (TTRX) has outperformed Zura Bio (ZURA) over the past year, gaining 30.4% versus a loss of 11.3%. Zura Bio is the larger company by market cap ($383.3 million vs $364.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TTRX | ZURA |
|---|---|---|
| Share price | $12.00 | $4.00 |
| Market cap | $364.41M | $383.32M |
| 1-day change | +5.36% | -3.15% |
| YTD return | +204.57% | -23.66% |
| 1-year return | +30.43% | -11.31% |
| EPS (TTM) | $-0.29 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.45 | $7.44 |
| 52-week low | $2.57 | $3.15 |
| Distance from 52-week high | -27.05% | -46.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +108.33% | +350.00% |
| Average volume | 109.59K | 1.44M |
| Shares outstanding | 30.37M | 95.83M |
| Employees | 2 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TTRX has outperformed ZURA by 41.7 percentage points over the past year.
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
TTRX vs ZURA FAQ
Which is bigger, Turn Therapeutics or Zura Bio?
Zura Bio (ZURA) is larger, with a market capitalization of $383.32M compared with $364.41M for Turn Therapeutics (TTRX).
Which stock has performed better over the past year, TTRX or ZURA?
TTRX returned +30.43% over the past 12 months, compared with -11.31% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Turn Therapeutics and Zura Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Turn Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Zura Bio.